Treatment of acute demyelinating optic neuritis

Seminars in Ophthalmology

Volumn 17, Issue 1, 2002, Pages 4-10

  Balcer, Laura J ^a   Galetta, Steven L ^a  

^a Department of Neurology ^*  (United States)

Author keywords

Interferon beta 1a; Methylprednisolone; Multiple sclerosis; Optic neuritis; Treatment

Indexed keywords

4 AMINOPYRIDINE; BETA1A INTERFERON; CORTICOSTEROID; GABAPENTIN; IMMUNOGLOBULIN; INTERFERON; METHYLPREDNISOLONE SODIUM SUCCINATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE;

ACUTE DISEASE; ADOLESCENT; ADULT; ANIMAL MODEL; CHILD; CLINICAL TRIAL; CONTRAST SENSITIVITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DRUG INDUCED DISEASE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK POPULATION; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SLEEP DISORDER; STEROID THERAPY; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; UHTHOFF PHENOMENON; VISUAL ACUITY; WEIGHT GAIN;

ACUTE DISEASE; CLINICAL TRIALS; DEMYELINATING DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; INTERFERON-BETA; OPTIC NEURITIS; PREDNISONE;

EID: 0036492291     PISSN: 08820538     EISSN: None     Source Type: Journal    
DOI: 10.1076/soph.17.1.4.10287     Document Type: Review

References (49)

1. The optic neuritis treatment trial
2. The clinical profile of acute optic neuritis: Experience of the Optic Neuritis Treatment Trial
3. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis
4. Visual loss: Optic neuropathies
5. Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology
6. Optic neuritis
7. Optic neuritis and multiple sclerosis: An epidemiologic study
8. Risk of developing multiple sclerosis after uncomplicated optic neuritis. A long-term prospective study
9. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis
10. The five-year risk of multiple sclerosis after optic neuritis: Experience of the Optic Neuritis Treatment Trial
11. The Optic Neuritis Treatment Trial: Implications for clinical practice
12. Intramuscular interferon beta-la therapy initiated during a first demyelinating event in multiple sclerosis
13. Interferon beta-la for optic neuritis patients at high risk for multiple sclerosis
14. Inflammatory optic neuropathies and neuroretinitis
15. Optic neuritis: A population-based study in Olmsted County, Minnesota
16. Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan
17. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan
18. Corticosteroid treatment of optic neuritis: A need to change treatment practices
19. Fellow eye abnormalities in acute unilateral optic neuritis: Experience of the Optic Neuritis Treatment Trial
20. Brain MRI in acute optic neuritis: Experience of the Optic Neuritis Study Group
21. Optic Neuritis Treatment Trial: One-year follow-up results
22. Baseline visual field profile of optic neuritis: The experience of the Optic Neuritis Treatment Trial
23. The course of visual recovery after optic neuritis: Experience of the Optic Neuritis Treatment Trial
24. Contrast sensitivity and other vision tests in the Optic Neuritis Treatment Trial
25. Visual function 5 years after optic neuritis: Experience of the Optic Neuritis Treatment Trial
26. Comparison of central and peripheral visual field properties in the Optic Neuritis Treatment Trial
27. Global visual field involvement in acute unilateral optic neuritis
28. Recovery of visual field function in the Optic Neuritis Treatment Trial
29. Visual field defects in the Optic Neuritis Treatment Trial: Central vs. peripheral, focal vs. global
30. Visual symptoms after optic neuritis: Results from the Optic Neuritis Treatment Trial
31. The National Eye Institute Visual Function Questionnaire: Experience of the ONTT
32. The impact of the Optic Neuritis Treatment Trial on the practices of ophthalmologists and neurologists
33. Optic neuritis in children: Clinical features and visual outcome
34. Risk factors for developing multiple sclerosis after childhood optic neuritis
35. Optic neuritis: Prognosis for multiple sclerosis from MRI, CSF, and HLA findings
36. The Tübingen Study on optic neuritis treatment: A prospective, randomized and controlled trial
37. A randomized, controlled trial of oral high-dose methylpred-nisolone in acute optic neuritis
38. Side effects of glucocorticoid treatment: Experience of the Optic Neuritis Treatment Trial
39. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
40. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study
41. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis
42. Oligodendrocyte proliferation and enhanced CNS remyelination after therapeutic manipulation of chronic relapsing EAE
43. Promotion of remyelination by polyclonal immunoglobulin and IVIg in Theiler's virus induced demyelination and in MS
44. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
45. Uhthoff's symptom in optic neuritis: Relationship to magnetic resonance imaging and development of multiple sclerosis
46. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis
47. The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis